Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05642429 · ClinicalTrials.gov registry record · Phase 1
Study of AV-1959D, an Amyloid Beta Vaccine
A Phase 1 study of Alzheimer Disease, sponsored by Institute for Molecular Medicine.
- Active
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 6
- Study locations
NCT05642429 is a Phase 1 study of Alzheimer Disease that is active but no longer recruiting, run by Institute for Molecular Medicine. The registered enrollment target is 48 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT05642429, a Phase 1 study of Alzheimer Disease, is active but no longer recruiting, sponsored by Institute for Molecular Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 6
- Study locations
Study Summary
Phase 1 clinical trial of AV-1959 amyloid-β vaccine for Alzheimer's disease (AD).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL AV-1959D
Study Locations (6)
Florida
- University of South Florida - Tampa
- Alzheimer's Research and Treatment Center - Wellington
Arizona
- Banner Alzheimer's Institute - Phoenix
California
- Hoag Memorial Hospital - Newport Beach
Georgia
- Accel Research - Decatur
New Jersey
- Global Medical Institutes Princeton Medical Institute - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2026-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05642429
The ClinicalTrials.gov registry entry for NCT05642429 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The listed sponsor is Institute for Molecular Medicine, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05642429 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT05642429 about?
NCT05642429 is a clinical study titled "Study of AV-1959D, an Amyloid Beta Vaccine". Phase 1 clinical trial of AV-1959 amyloid-β vaccine for Alzheimer's disease (AD).
What is the current status of trial NCT05642429?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-02-27. Estimated completion is 2026-11-07.
What conditions does trial NCT05642429 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT05642429?
The interventions under investigation include: Placebo (BIOLOGICAL), AV-1959D (BIOLOGICAL).
Who is sponsoring clinical trial NCT05642429?
This trial is sponsored by Institute for Molecular Medicine, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05642429 being conducted?
This trial has 6 study locations across Arizona, California, Florida, Georgia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.